Harnessing exosomes for targeted drug delivery systems to combat brain cancer

Abstract Brain cancer remains a significant challenge in the field of oncology, primarily because of its aggressive nature and the limited treatment options available. Conventional therapies often fall short in effectively targeting tumor cells, while sparing healthy brain tissue from collateral dam...

Full description

Saved in:
Bibliographic Details
Main Authors: Abdullah E. Basyoni, Amira Atta, Maha M. Salem, Tarek M. Mohamed
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Cancer Cell International
Subjects:
Online Access:https://doi.org/10.1186/s12935-025-03731-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850148905783656448
author Abdullah E. Basyoni
Amira Atta
Maha M. Salem
Tarek M. Mohamed
author_facet Abdullah E. Basyoni
Amira Atta
Maha M. Salem
Tarek M. Mohamed
author_sort Abdullah E. Basyoni
collection DOAJ
description Abstract Brain cancer remains a significant challenge in the field of oncology, primarily because of its aggressive nature and the limited treatment options available. Conventional therapies often fall short in effectively targeting tumor cells, while sparing healthy brain tissue from collateral damage. However, exosomes are now recognized as promising nanocarriers for targeted drug delivery. These naturally occurring extracellular vesicles can cross the blood–brain barrier and selectively interact with cancer cells. Utilizing exosomes as drug delivery vehicles offers a novel approach with significant potential for targeted therapy. By encapsulating therapeutic agents within exosomes, drugs can be specifically targeted to tumor cells, maximizing their impact whilst minimizing damage to healthy brain tissue. Furthermore, exosomes can be modified to display molecules that specifically recognize and bind to cancer cells, further enhancing their precision and efficacy. While exosome-based therapies show potential, scalability, purification, and clinical application challenges remain. The scalability of exosome production, purification, and modification techniques remains a hurdle that must be overcome for clinical translation. Additionally, the intricate interactions between the tumor microenvironment and exosomes necessitate further research to optimize therapeutic outcomes. The review explores applications and future perspectives of exosome-based therapies in advancing targeted brain cancer treatment.
format Article
id doaj-art-d1f73a3546434f92992e6d2b46fe64f7
institution OA Journals
issn 1475-2867
language English
publishDate 2025-04-01
publisher BMC
record_format Article
series Cancer Cell International
spelling doaj-art-d1f73a3546434f92992e6d2b46fe64f72025-08-20T02:27:06ZengBMCCancer Cell International1475-28672025-04-0125113210.1186/s12935-025-03731-zHarnessing exosomes for targeted drug delivery systems to combat brain cancerAbdullah E. Basyoni0Amira Atta1Maha M. Salem2Tarek M. Mohamed3Biochemistry Division, Chemistry Department, Faculty of Science, Tanta UniversityBiochemistry Division, Chemistry Department, Faculty of Science, Tanta UniversityBiochemistry Division, Chemistry Department, Faculty of Science, Tanta UniversityBiochemistry Division, Chemistry Department, Faculty of Science, Tanta UniversityAbstract Brain cancer remains a significant challenge in the field of oncology, primarily because of its aggressive nature and the limited treatment options available. Conventional therapies often fall short in effectively targeting tumor cells, while sparing healthy brain tissue from collateral damage. However, exosomes are now recognized as promising nanocarriers for targeted drug delivery. These naturally occurring extracellular vesicles can cross the blood–brain barrier and selectively interact with cancer cells. Utilizing exosomes as drug delivery vehicles offers a novel approach with significant potential for targeted therapy. By encapsulating therapeutic agents within exosomes, drugs can be specifically targeted to tumor cells, maximizing their impact whilst minimizing damage to healthy brain tissue. Furthermore, exosomes can be modified to display molecules that specifically recognize and bind to cancer cells, further enhancing their precision and efficacy. While exosome-based therapies show potential, scalability, purification, and clinical application challenges remain. The scalability of exosome production, purification, and modification techniques remains a hurdle that must be overcome for clinical translation. Additionally, the intricate interactions between the tumor microenvironment and exosomes necessitate further research to optimize therapeutic outcomes. The review explores applications and future perspectives of exosome-based therapies in advancing targeted brain cancer treatment.https://doi.org/10.1186/s12935-025-03731-zExosomesNanocarriersBrain cancerTargeted drug delivery
spellingShingle Abdullah E. Basyoni
Amira Atta
Maha M. Salem
Tarek M. Mohamed
Harnessing exosomes for targeted drug delivery systems to combat brain cancer
Cancer Cell International
Exosomes
Nanocarriers
Brain cancer
Targeted drug delivery
title Harnessing exosomes for targeted drug delivery systems to combat brain cancer
title_full Harnessing exosomes for targeted drug delivery systems to combat brain cancer
title_fullStr Harnessing exosomes for targeted drug delivery systems to combat brain cancer
title_full_unstemmed Harnessing exosomes for targeted drug delivery systems to combat brain cancer
title_short Harnessing exosomes for targeted drug delivery systems to combat brain cancer
title_sort harnessing exosomes for targeted drug delivery systems to combat brain cancer
topic Exosomes
Nanocarriers
Brain cancer
Targeted drug delivery
url https://doi.org/10.1186/s12935-025-03731-z
work_keys_str_mv AT abdullahebasyoni harnessingexosomesfortargeteddrugdeliverysystemstocombatbraincancer
AT amiraatta harnessingexosomesfortargeteddrugdeliverysystemstocombatbraincancer
AT mahamsalem harnessingexosomesfortargeteddrugdeliverysystemstocombatbraincancer
AT tarekmmohamed harnessingexosomesfortargeteddrugdeliverysystemstocombatbraincancer